Manages acute pain severe enough to require an opioid analgesic. ANDA 207152, held by Aurobindo Pharma. Acetaminophen; Tramadol Hydrochloride.
As of Nov 21, 2026, ANDA 207152 (Tramadol Hydrochloride and Acetaminophen), held by Aurobindo Pharma, was first approved by FDA on Mar 22, 2017, with 11 approved supplements and 0 published complete response letters.
Tramadol hydrochloride and acetaminophen tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Tramadol hydrochlorideandacetaminophen tablets are indicated for short-term use of five days or less. Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve tramadol hydrochloride and acetaminophen tablets for use in patients for whom alternative treatment options (e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tramadol Hydrochloride and Acetaminophen325MG;37.5MG · tablet;oral | Acetaminophen; Tramadol Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 21REMS | Approved | None posted |
| Dec 29, 2025 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 15, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 17REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 4REMS | Approved | None posted |
| Mar 22, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters